Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis

Thrombosis and Haemostasis

Volumn 107, Issue 4, 2012, Pages 769-774

  Stein, Andreas ^a   Mohr, Felix ^a   Laux, Magdalena ^a   Thieme, Stefanie ^a   Lorenz, Barbara ^a   Cetindis, Mirijam ^a   Hackl, Janina ^a   Groha, Philipp ^a   Demetz, Gabriele ^a   Schulz, Stefanie ^a   Mehilli, Julinda ^a   Schömig, Albert ^a   Kastrati, Adnan ^a   Ott, Ilka ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Myocardial infarction; Progenitor cells; Restenosis

Indexed keywords

C REACTIVE PROTEIN; CD133 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; ERYTHROPOIETIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ANGIOCARDIOGRAPHY; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG MEGADOSE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NEOINTIMA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; RETICULOCYTE; ST SEGMENT ELEVATIONMYOCARDIAL INFARCTION; STEM CELL MOBILIZATION; TREATMENT OUTCOME;

ANGIOGRAPHY; CYTOKINES; DRUG-ELUTING STENTS; ERYTHROPOIETIN; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; INFLAMMATION; INTERLEUKINS; MYOCARDIAL INFARCTION; PLACEBOS; RECOMBINANT PROTEINS; STEM CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84859368408     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-08-0552     Document Type: Article

References (27)

1. Latini R, Brines M, Fiordaliso F. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev 2008; 13: 415-423.
2. Brunner S, Winogradow J, Huber BC, et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the cxcr-4/sdf-1 axis. Faseb J 2009; 23: 351-361.
3. Fiordaliso F, Chimenti S, Staszewsky L, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005; 102: 2046-2051.
4. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006; 48: 176-184.
5. Moon C, Krawczyk M, Ahn D, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003; 100: 11612-11617.
6. van der Meer P, Lipsic E, Henning RH, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005; 46: 125-133.
7. Westenbrink BD, Lipsic E, van der Meer P, et al Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 2007; 28: 2018-2027.
8. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
9. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
10. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
11. Ott I, Schulz S, Mehilli J, et al. Erythropoietin in patients with acute st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3: 408-413.
12. Urao N, Okigaki M, Yamada H, et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 2006; 98: 1405-1413.
13. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 1999; 18: 3964-3972.
14. Heimfeld S, Fogarty B, McGuire K, et al. Peripheral blood stem cell mobilization after stem cell factor or g-csf treatment: Rapid enrichment for stem and progenitor cells using the ceprate immunoaffinity separation system. Transplant Proc 1992; 24: 2818.
15. Kessinger A, Bishop MR, Jackson JD, et al. Erythropoietin for mobilization of circulating progenitor cells in patients with previously treated relapsed malignancies. Exp Hematol 1995; 23: 609-612.
16. Schomig K, Busch G, Steppich B, et al. Interleukin-8 is associated with circulating cd133+ progenitor cells in acute myocardial infarction. Eur Heart J 2006; 27: 1032-1037.
17. Minatoguchi S, Takemura G, Chen XH, et al. Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 2004; 109: 2572-2580.
18. Harada M, Qin Y, Takano H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the jak-stat pathway in cardiomyocytes. Nat Med 2005; 11: 305-311.
19. Sugano Y, Anzai T, Yoshikawa T, et al. Granulocyte colony-stimulating factor attenuates early ventricular expansion after experimental myocardial infarction. Cardiovasc Res 2005; 65: 446-456.
20. Zohlnhofer D. G-CSF for left ventricular recovery after myocardial infarction: Is it time to face reality? Cardiovasc Drugs Ther 2008; 22: 343-345.
21. Zohlnhofer D, Kastrati A, Schomig A. Stem cell mobilization by granulocyte-colony-stimulating factor in acute myocardial infarction: Lessons from the revival-2 trial. Nat Clin Pract Cardiovasc Med 2007; 4 (Suppl 1): S106-109.
22. Stein A, Zohlnhofer D, Pogatsa-Murray G, et al. Expression of CXCR4, VLA-1, LFA-3 and transducer of erb in G-CSF-mobilised progenitor cells in acute myocardial infarction. Thromb Haemost 2010: 103: 638-643.
23. Janmaat ML, Heerkens JL, de Bruin AM, et al. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood 2010; 115: 1453-1460.
24. Li Y, Takemura G, Okada H, et al. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 2006; 71: 684-694.
25. Li JJ, Ren Y, Chen KJ, et al. Impact of c-reactive protein on in-stent restenosis: A meta-analysis. Tex Heart Inst J 2010; 37: 49-57.
26. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity c-reactive protein assay. Clin Chem 1999; 45: 2136-2141.
27. Sen S, McDonald SP, Coates PT, Bonder CS. Endothelial progenitor cells: Novel biomarker and promising cell therapy for cardiovascular disease. Clin Sci 2010; 120: 263-283.